Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Aug;25(8):993-6.
doi: 10.1111/j.1464-5491.2008.02485.x.

Perinatal outcomes associated with the use of glargine during pregnancy

G Di Cianni  1 , E Torlone, C Lencioni, M Bonomo, A Di Benedetto, A Napoli, E Vitacolonna, D Mannino, A Lapolla; Italian Diabetes and Pregnancy Study Group; Italian Society of Diabetology
Collaborators, Affiliations
Free PMC article
Multicenter Study

Perinatal outcomes associated with the use of glargine during pregnancy

G Di Cianni et al. Diabet Med. 2008 Aug.
Free PMC article

Abstract

Aims: Insulin glargine (IG), with its non-peaking action profile, might be useful in diabetic pregnancy. However, data on its safety are limited and its use during pregnancy is not recommended. This study focused on the effects of IG on perinatal outcome, particularly to estimate the rate of congenital anomalies and birthweight.

Methods: This retrospective study included women with pre-gestational diabetes who used IG before (at least 1 month) and during pregnancy. For all women we recorded data regarding maternal glycaemic control and pregnancy outcome. We also compared women treated with IG throughout pregnancy and women who stopped taking IG at an earlier stage.

Results: From 27 centres, 107 Type 1 diabetic pregnancies were identified. IG was started 10.3 +/- 6.9 months before conception and in 57.4% of cases was stopped during the first trimester; 42.6% of women continued using it until the end of pregnancy. There were six abortions (four spontaneous and two induced) and five newborns (4.9%) with congenital anomalies. Glycaemic control, birthweight and the prevalence of macrosomia and neonatal morbidity were similar in women who used IG for the full term compared with those who stopped IG earlier during pregnancy.

Conclusions: This study, although limited, suggests that IG is safe and effective; the rate of congenital malformations was within the range expected for diabetic pregnancies treated with more traditional forms of insulin. IG used throughout pregnancy did not seem to influence birthweight or increase adverse outcomes.

PubMed Disclaimer

References

    1. Owens DR, Zinnan B, Bolli GB. Insulin today and beyond. Lancet. 2001;358:739–746. - PubMed
    1. Temple R, Aldrige V, Greenwood R, Heypurn B, Sampson M, Stanley K. Association between outcome of pregnancy and glycaemic control in early pregnancy in Type 1 diabetes: a population-based study. Br Med J. 2002;325:1275–1276. - PMC - PubMed
    1. Manderson JG, Patterson CC, Hadden DR, Traub Al, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in Type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003;189:507–512. - PubMed
    1. Slieker LJ, Brooke GS, Di Marchi R, Flora D, Green LK, Hoffmann JA. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia. 1997;40:54–61. - PubMed
    1. Devlin JT, Hothershall L, Wilkis JL. Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabetes Care. 2002;25:1095–1096. - PubMed

Publication types

MeSH terms